Stopping GLP-1 receptor agonists 14 days prior to total hip or knee arthroplasty may reduce several key risk factors ...

The surge of online weight-loss drug providers is unexpectedly fueling demand for a much older, once-stigmatized treatment: ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

ABC News' Dr. Tara Narula breaks down the FDA's decision to stop the making of compound versions of weight loss medications.

Beyond type 2 diabetes and weight loss, GLP-1 agonists can also help lower blood pressure, improve lipid disorders, reduce ...

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Preoperative glucagon-like peptide-1 receptor agonist use is not associated with short-term postoperative aspiration pneumonia.

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Vivani Medical (Nasdaq:VANI) today announced steps enabling it to focus solely on its GLP-1-delivering implant technologies.

Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...